Resveratrol protects left ventricle by increasing adenylate kinase and isocitrate dehydrogenase activities in rats with myocardial infarction.
Our prior study had shown that resveratrol was a potent cardioprotective agent in rats with myocardial infarction (MI). In this study, we further evaluated the mechanism of cardioprotection of resveratrol by proteomic analysis. After permanent ligation of the left anterior descending artery under isoflurane anesthesia, surviving rats were randomly allocated to three groups and treated with resveratrol at 1 mg/kg/day (MI/R group), or vehicles (sham group and MI group) once daily for four weeks. In proteomic analysis, the MI group showed decreased expression of adenylate kinase 1 (AK1) and mitochondrial NADP⁺-dependent isocitrate dehydrogenase (IDPm) after MI compared with the sham group. These variations were reversed by resveratrol in the MI/R group. Validation with Western blot and immunohistochemical analyses showed similar trends in protein expression profiling. Our studies suggest that the beneficial effects of resveratrol on ventricular modeling may be due to increased expression of AK1 and IDPm, which have been known to increase myocardial energetic efficiency and reduce reactive oxygen species-mediated damage, respectively.
Division of Cardiology, Buddhist Tzu Chi General Hospital, Taiwan, Republic of China.
Jeng-Feng
JF
Lin
Semon
S
Wu
Shiang-Suo
SS
Huang
Bo-Yi
BY
Lu
Su-Man
SM
Lin
Shen-Kou
SK
Tsai
D000263:Adenylate Kinase / Q000032:analysis / Q000378:metabolism*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D015153:Blotting, Western; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D015180:Electrophoresis, Gel, Two-Dimensional; D004734:Energy Metabolism / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D007150:Immunohistochemistry; D007521:Isocitrate Dehydrogenase / Q000032:analysis / Q000378:metabolism*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D020257:Ventricular Remodeling / Q000187:drug effects
D000975:Antioxidants; D002316:Cardiotonic Agents; D013267:Stilbenes; D007521:Isocitrate Dehydrogenase; D000263:Adenylate Kinase; C110939:adenylate kinase 1; D000077185:Resveratrol